WHO Classification of of Tumours of the Urinary System and Male Genital Organs

By T. Ulbright, M. Amin, Bonnie L. Balzer, D. Berney, Jonathan I. Epstein, Charles C. Guo, Muhammad T. Idrees, Leendert H. J. Looijenga, G. Paner, E. R. Meyts and 4 more. 2016

1,029 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/874eaee8d682bca1aa53fc75236b27486737d029

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Babjuk
2. M. Burger
3. G. Rindi
4. D. Klimstra
5. Marko Babjuk
6. E. Brambilla
7. M. Rouprêt
8. W. Travis

Citations in the corpus

• European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). (2021, methodology): “Use of T1 substaging is recommended by the 2016 World Health Organization (WHO) classification [17].”
• European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. (2020, unknown): “In 2016, an update of the 2004 WHO grading classification was published without major changes [33].”
• A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal (2018, background): “NETs in the kidney, formerly designated carcinoid tumors, are extremely rare, and high-grade NENs arising from the renal pelvic mucosa must be excluded before the diagnosis of NEN of renal parenchyma because they are more common than tumors of renal origin [98].”
• European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. (2019, methodology): “Its use is recommended by the 2016 World Health Organization (WHO) classification [12].”